Table 2.
Neurological abnormalities at initiation and 12 months after start of HAART in children with HIV encephalopathy (n = 64)
| Clinical parameters | Initiation of HAART, n (%) | 12 months post-HAART, n (%)a |
|---|---|---|
| Hyperreflexia | 55 (86.0) | 49 (76.6) |
| Delayed milestones | 53 (82.9) | 45 (70.4) |
| Spasticity | 45 (70.3) | 41 (64.1) |
| Microcephaly | 37 (57.8) | 37 (57.8) |
| Quadriparesis | 16 (25.0) | 13 (20.4) |
| Milestone regression | 13 (20.3) | 9 (14.1) |
| Poor learning | 13 (20.3) | 18 (28.1) |
| Ataxia | 11 (17.2) | 20 (31.3) |
| Diplegia | 10 (15.6) | 13 (20.4) |
| Hemiplegia | 4 (6.3) | 4 (6.3) |
| Poor behavior | 3 (4.7) | 3 (4.7) |
| Poor coordination | 1 (1.6) | 1 (1.6) |
HAART, highly active antiretroviral therapy.
a
By paired t-test, all p > 0.05.